Welcome to our dedicated page for Sharps Tech SEC filings (Ticker: STSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sharps Technology Inc. (NASDAQ: STSS) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into how Sharps Technology describes its medical device activities, smart-safety syringe and pharmaceutical packaging products, medical device distribution operations, and its Solana-based digital asset treasury strategy.
Through periodic reports such as the Form 10-K annual report and Form 10-Q quarterly reports, investors can review information on business segments, risk factors related to medical devices and digital assets, capital structure, and the financial impact of activities like SOL acquisitions, staking revenue, and fair-value changes. Current reports on Form 8-K highlight material events, including the launch and terms of large private placements, the authorization of a $100 million stock repurchase program, entry into share repurchase agreements, settlement agreements involving asset transfers, and special stockholder meeting outcomes related to warrant share issuances.
Proxy materials such as the DEF 14A definitive proxy statement provide additional context on governance matters, including director elections and proposals to approve the issuance of shares upon the exercise of cryptocurrency-related pre-funded and stapled warrants and strategic advisor warrants. Together, these filings outline how Sharps Technology structures its capital markets activity to support both its medical device distribution business and its Solana-focused treasury model.
On Stock Titan, these SEC filings are updated in real time from EDGAR and are paired with AI-powered summaries that explain key points in plain language. Users can quickly understand the implications of lengthy 10-K and 10-Q reports, review 8-K disclosures about treasury strategy developments or repurchase programs, and track warrant-related approvals and other corporate actions. This page also surfaces information relevant to insider and major holder activity through ownership and transaction filings when available, helping investors analyze how Sharps Technology’s leadership and significant holders interact with the company’s equity over time.
Reporting person Zhang Yuwen, Chief Investment Officer and director of Sharps Technology Inc. (STSS), reported a grant of stock options on
Sharps Technology Inc. (STSS) director and Chief Investment Officer Yuwen Zhang filed an initial Form 3 reporting indirect beneficial ownership of 14,040 shares of common stock that are held indirectly through a spouse. The event date listed is
Sharps Technology, Inc. entered into a confidential settlement agreement to resolve litigation with Barry Berler and several Plasto-related entities.
Under this settlement, Sharps will transfer certain assets to Plasto Technology Group LLC, including all of its right, title and interest in the issued and outstanding shares of its Hungarian subsidiary, Safegard Medical Kft, as well as specified patents, registered trademarks and associated goodwill.
All parties agree to unconditionally and irrevocably release one another and their representatives from all claims in the litigation, and the agreement specifies that no party admits fault, responsibility or liability. Sharps also provides unaudited pro forma condensed consolidated financial information as an exhibit to show the impact of these changes.
Sharps Technology, Inc. entered into a Waiver and Consent on September 26, 2025 with certain security holders who collectively beneficially own at least 50.1% of the outstanding Registrable Securities under its August 25, 2025 Registration Rights Agreement. This Waiver and Consent waives the original September 29, 2025 filing date and extends the deadline for Sharps Technology to file its initial resale registration statement with the SEC to the 60th calendar day following the Closing Date defined in that agreement. The company has filed the Waiver and Consent and the Registration Rights Agreement as exhibits for investors to review.
Sharps Technology, Inc. filed a Definitive Proxy Statement asking shareholders to vote on four proposals at a special meeting, principally the approval to issue up to 49,673,120 shares of common stock upon exercise of outstanding Cryptocurrency Warrants and a separate approval for issuance upon exercise of Strategic Advisor Warrants. The filing lists board nominees and executive officers, including Paul K. Danner as Executive Chairman and Principal Executive Officer and Andrew R. Crescenzo as CFO. The statement notes the threshold rule that an issuance equaling or exceeding 20% of outstanding common stock requires shareholder approval. Specific beneficial ownership lines are summarized with individual directors and officers holding less than 1% each.
Sharps Technology, Inc. submitted a Form S-3 shelf registration to offer multiple classes of securities, including common stock, preferred stock, warrants, purchase contracts, subscription rights, depositary shares and units combining those instruments. The filing includes a standard prospectus table of contents covering the prospectus summary, risk factors, use of proceeds, description of securities, plan of distribution and exhibits.
The document highlights industry risk linked to the Solana cryptocurrency ecosystem, noting uncertainty from factors such as worldwide adoption of SOL, regulatory or access restrictions, maintenance of open-source protocols, shifts in consumer preferences and general economic and regulatory conditions affecting cryptocurrency service providers. The filing discloses estimated offering-related fees and expenses with a total of